Physician profile
Steven Koopman
NPI 1811199573
$48,511.29
in general payments reported to CMS, 2019-2025
43 companies · $16K in 2025
The $16K reported for 2025 was more than what 96% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,607 · 2020: $528 · 2021: $489 · 2022: $3,932 · 2023: $6,916 · 2024: $16K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $35K · Food and Beverage: $2,655 · Travel and Lodging: $1,511 · Education: $39.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $34,750.00 |
| Food and Beverage | $2,654.73 |
| Travel and Lodging | $1,510.53 |
| Education | $39.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $38,148.85 | 2022-2025 | Nanoknife, Nanoknife |
| Janssen Biotech, INC. | $3,723.65 | 2019-2023 | Erleada |
| Procept Biorobotics Corporation | $1,609.30 | 2021-2025 | Aquabeam Robotic System, Aquabeam System |
| Histosonics, INC. | $819.43 | 2025 | |
| Astellas Pharma US INC | $623.43 | 2019-2025 | Xtandi |
| Abbvie INC. | $397.37 | 2019-2025 | |
| Antares Pharma, INC. | $383.64 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Olympus America INC. | $352.73 | 2020-2025 | Itind System |
| Pfizer INC. | $317.78 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $265.56 | 2019-2025 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $245.90 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $203.40 | 2023-2025 | Gemtesa |
| Boston Scientific Corporation | $170.97 | 2019-2023 | Rezum Generator |
| Merck Sharp & Dohme LLC | $165.67 | 2019-2023 | Lynparza, Keytruda |
| Tolmar, INC. | $116.33 | 2023-2024 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Koopman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.